ASCO 2019

Area: Oncology

Location: Chicago, United States

Date: May 31 to June 4

Description:

American Society of Clinical Oncology.


Search in Scientific Content:
Date
Filters:
Immunother
4:09

Immunotherapies in Thymic Malignancies

Presenter: Heather A. Wakelee
Oncology : Lymphoma
Will There
2:57

Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine

Presenter: Priscilla Kaliopi Brastianos
Oncology : Lymphoma
Highlights
6:24

Highlights of prostate cancer research at ASCO2019

Presenter: Oliver Sartor
Oncology : Lymphoma
A randomiz
2:15

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma

Presenter: Jian-Ming Xu
Oncology : Lymphoma
Activity a
2:30

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Presenter: Patrick Schoeffski
Oncology : Lymphoma
To Infinit
5:25

To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies

Presenter: Oliver Dorigo
Oncology : Lymphoma
Hematologi...
8:54

Hematologic Malignancies—Plasma Cell Dyscrasia

Presenter: Noopur S. Raje
Oncology : Lymphoma
Sarcoma
5:60

Sarcoma

Presenter: Shreyaskumar Patel
Oncology : Lymphoma
ANNOUNCE:
4:55

ANNOUNCE: A randomized, placebo-controlled, double-blind, phase III trial of doxorubicin + olaratumab versus dox + PBO in patients with advanced soft tissue sarcomas

Presenter: William D. Tap
Oncology : Lymphoma
Targeting
8:34

Targeting Breast Cancer: Breaking the Code

Presenter: Julia R. White
Oncology : Lymphoma
Interim re
5:04

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Presenter: Emmanuel S. Antonarakis
Oncology : Lymphoma
Should Imm
4:38

Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?

Presenter: Ramon Andrade De Mello
Oncology : Lymphoma
Nivolumab
2:58

Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275

Presenter: Arlene O. Siefker-Radtke
Oncology : Lymphoma
Identifica
7:08

Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Presenter: Donald Williams Parsons
Oncology : Lymphoma
Highlights
7:33

Highlights of the Metastatic Breast Cancer Session

Presenter: Sara M. Tolaney
Oncology : Lymphoma
Antiangiog
6:15

Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1

Presenter: Guru Sonpavde
Oncology : Lymphoma

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia

ESMO 2014

2014-09-26 - 2014-09-30
Madrid, Spain